In a report released yesterday, Matt Phipps from William Blair maintained a Hold rating on Amgen (AMGN). The company’s shares closed last Monday at $226.91.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of 13.1% and a 54.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aileron Therapeutics, and Autolus Therapeutics.
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $250.53.
See today’s analyst top recommended stocks >>
Based on Amgen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.16 billion and net profit of $1.83 billion. In comparison, last year the company earned revenue of $5.56 billion and had a net profit of $1.99 billion.
Based on the recent corporate insider activity of 89 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Read More on AMGN: